Sharp Launches Clinventory IMS
Sharp, part of UDG Healthcare plc, has launched a new Inventory Management System (IMS) to support clinical trial sponsors in managing inventory and supplies.
The new system—named Clinventory—has been designed to provide full visibility of stock levels at investigator sites and tracking product through the supply chain.
Using the Clinventory IMS will also create efficiencies for trial sponsors by aiming to improve the drug management process by leveraging automation to increase reliability.
Sascha Sonnenberg, Global Head of Business Development at Sharp Clinical said “Clinventory has been designed specifically with those smaller-volume, early stage or open label clinical trials in mind, where a larger, more expensive inventory system might offer an array of functionality that is surplus to needs.”
Read the full release and learn more, here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
